Evaxion Biotech A/S (EVAX) Competitors

Aptose Biosciences (NASDAQ:APTO) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends.

Which has more risk & volatility, APTO or EVAX?

Aptose Biosciences has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of APTO or EVAX?

26.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are owned by institutional investors. 9.5% of Aptose Biosciences shares are owned by company insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is APTO or EVAX more profitable?

Aptose Biosciences' return on equity of -451.63% beat Evaxion Biotech A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	-458.70%	-205.30%
Evaxion Biotech A/S	N/A	-451.63%	-149.27%

Does the MarketBeat Community favor APTO or EVAX?

Aptose Biosciences received 358 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. Likewise, 65.91% of users gave Aptose Biosciences an outperform vote while only 56.67% of users gave Evaxion Biotech A/S an outperform vote.

Company	Underperform	Outperform
Aptose Biosciences	Outperform Votes 375 65.91%	Underperform Votes 194 34.09%
Evaxion Biotech A/S	Outperform Votes 17 56.67%	Underperform Votes 13 43.33%

Which has higher valuation and earnings, APTO or EVAX?

Evaxion Biotech A/S has higher revenue and earnings than Aptose Biosciences. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-$51.21M	-$7.72	-0.16
Evaxion Biotech A/S	$70K	322.89	-$22.12M	-$6.76	-0.64

Does the media favor APTO or EVAX?

In the previous week, Aptose Biosciences had 1 more articles in the media than Evaxion Biotech A/S. MarketBeat recorded 2 mentions for Aptose Biosciences and 1 mentions for Evaxion Biotech A/S. Evaxion Biotech A/S's average media sentiment score of 1.00 beat Aptose Biosciences' score of -1.00 indicating that Aptose Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Aptose Biosciences	Positive
Evaxion Biotech A/S	Negative

Do analysts rate APTO or EVAX?

Aptose Biosciences presently has a consensus target price of $19.80, indicating a potential upside of 1,509.76%. Evaxion Biotech A/S has a consensus target price of $11.00, indicating a potential upside of 164.42%. Given Evaxion Biotech A/S's higher possible upside, equities research analysts plainly believe Aptose Biosciences is more favorable than Evaxion Biotech A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Evaxion Biotech A/S	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Aptose Biosciences beats Evaxion Biotech A/S on 9 of the 15 factors compared between the two stocks.